YABAO PHARM.CORP: ZY-A002 has received the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.YABAO PHARM.CORP recently received approval from the National Medical Products Administration for the clinical trial notification of the drug ZY-A002, with the number 2025LP02459. This drug will be used for confirmatory clinical trials of cough variant asthma in children, with indications including dispelling wind and promoting lung function, relieving spasms and stopping cough, primarily targeting symptoms such as coughing fits and throat itching
According to the Zhitong Finance APP, YABAO PHARM.CORP (600351.SH) announced that it has recently received the "Drug Clinical Trial Approval Notice" for ZY-A002 issued by the National Medical Products Administration (Notice No.: 2025LP02459), which approves the product to conduct confirmatory clinical trials for pediatric cough variant asthma.
The indication for ZY-A002 is to dispel wind and promote lung function, relieve spasms, and stop cough, mainly used for pediatric cough variant asthma (wind pathogen affecting the lung syndrome), characterized by paroxysmal cough, itchy throat leading to cough, little or no phlegm, or clear nasal discharge, with a pale tongue, thin white coating, and wiry pulse